Longitudinal impact of the Women’s Health Initiative study on hormone therapy use in Australia

References

• Brown S. Shock, terror and controversy: how the media reacted to the Women's Health Initiative. Climacteric 2012;15:275–80
   PubMed Web of Science ®Google Scholar
• Writing group for the Women's Health Initiative investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321–33
   PubMed Web of Science ®Google Scholar
• Coombs NJ, Boyages J. Changes in HT prescriptions in Australia since 1992. Aust Fam Physician 2005;34:697–8
   PubMedGoogle Scholar
• Wysowski DK, Governale LA. Use of menopausal hormones in the United States, 1992 through June, 2003. Pharmacoepidemiol Drug Saf 2005;14:171–6
   PubMed Web of Science ®Google Scholar
• Nabulsi AA, Folsom AR, White A, et al. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. The atherosclerosis risk in communities study investigators N Engl J Med 1993;328:1069–75
   PubMed Web of Science ®Google Scholar
• Stoppe G, Dören M. Critical appraisal of effects of estrogen replacement therapy on symptoms of depressed mood. Arch Women Ment Health 2002;5:39–47
   PubMedGoogle Scholar
• Sahin NH, Bal MD, Boğğa NM, et al. Women's perception of the menopause and hormone treatment: barriers against hormone therapy. Climacteric 2011;14:152–6
   PubMed Web of Science ®Google Scholar
• Main P, Robinson M. Changes in utilisation of hormone replacement therapy in Australia following publication of the findings of the Women's Health Initiative. Pharmacoepidemiol Drug Saf 2008;17:861–8
   PubMed Web of Science ®Google Scholar
• Vegter S, Kolling P, Toben M, et al. Replacing hormone therapy–is the decline in prescribing sustained, and are nonhormonal drugs substituted? Menopause 2009;16:329–35
   PubMed Web of Science ®Google Scholar
• Ameye L, Antoine C, Paesmans M, et al. Menopausal hormone therapy use in 17 European countries during the last decade. Maturitas 2014;79:287–91
   PubMed Web of Science ®Google Scholar
• BaladéMartínez L, Montero Corominas D, Macías Saint-Gerons D. Utilization of hormone replacement therapy in Spain: trends in the period 2000–2014. Med Clin (Barc) 2016;147:287–92
   PubMed Web of Science ®Google Scholar
• Weissfeld JL, Liu W, Woods C, et al. Trends in oral and vaginally administered estrogen use among US women 50 years of age or older with commercial health insurance. Menopause 2018;25:611–4
   PubMed Web of Science ®Google Scholar
• Lawton B, Rose S, McLeod D, et al. Changes in use of hormone replacement therapy after the report from the Women's Health Initiative: cross sectional survey of users. BMJ 2003;327:845
   PubMed Web of Science ®Google Scholar
• The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701–12
   PubMed Web of Science ®Google Scholar
• Pines A, Sturdee DW, Birkhäuser MH, et al. IMS updated recommendations on postmenopausal hormone therapy. Climacteric 2007;10:181–94
   PubMed Web of Science ®Google Scholar
• Stephenson J. FDA orders estrogen safety warnings. JAMA 2003;289:537–8
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465–77
   PubMed Web of Science ®Google Scholar
• de Villiers TJ, Pines A, Panay N, et al. Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric 2013;16:316–37
   PubMed Web of Science ®Google Scholar
• de Villiers TJ, Gass ML, Haines CJ, et al. Global Consensus Statement on menopausal hormone therapy. Climacteric 2013;16:203–4
   PubMed Web of Science ®Google Scholar
• Biglan A, Ary D, Wagenaar AC The value of interrupted time-series experiments for community intervention research. Prev Sci 2000;1:31–49
   PubMedGoogle Scholar
• Wagner AK, Soumerai SB, Zhang F, et al. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther 2002;27:299–309
   PubMed Web of Science ®Google Scholar
• Pharmaceutical Benefit Schedule item statistics [Internet]. Canberra: Australian Government Department of Human Services; 2017. Available from: http://medicarestatistics.humanservices.gov.au/statistics/pbs_item.jsp [cited 2017 Feb 24]
   Google Scholar
• PBS publication archive [Internet]. Canberra: Australian Government Department of Health; 2017. Available from: http://www.pbs.gov.au/info/publication/schedule/archive [cited 2017 Feb 24]
   Google Scholar
• QuintilesIMS. Australian Pharmaceutical Index: Complementary audit data. Sydney, Australia: QuintilesIMS; 2017
   Google Scholar
• Australian Register of Therapeutic Goods [Internet]. Canberra: Therapeutic Good Administration; 2016. Available from: https://www.tga.gov.au/australian-register-therapeutic-goods [cited 2017 Feb 11]
   Google Scholar
• ATC/DDD Index [Internet]. Oslo: WHO Collaborating Centre for Drug Statistics Methodology; 2017. Available from: https://www.whocc.no/atc_ddd_index/ [cited 2017 Feb 24]
   Google Scholar
• Menopause. eTG Complete. Melbourne, Australia: Therapeutic Guidelines Limited; 2018
   Google Scholar
• World Health Organization. Introduction to drug utilization research. Oslo, Norway: WHO; 2003
   Google Scholar
• Barnett AG, Dobson AJ, Analysing seasonal health data. Berlin, Heidelberg, Germany: Springer; 2010:49–74
   Google Scholar
• Hyndman RJ, Athanasopoulos G, Forecasting: Principles and practice, 2nd Edition. Melbourne, Australia: OTexts; 2017:Chapter 9 Dynamics regression models
   Google Scholar
• Hyndman RJ, Athanasopoulos G, Bergmeir C, et al. forecast: Forecasting functions for time series and linear models. R package version 8.4, 2018
   Google Scholar
• R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2017
   Google Scholar
• Altman DG, Bland JM. How to obtain the p value from a confidence interval. BMJ 2011;343:1–2
   Google Scholar
• Holm E, Aaltonen K, Heikkinen AM, et al. From systemic hormone therapy to vaginal estrogen – a nationwide register study in Finland, 2003–2012. Maturitas 2014;78:293–7
   PubMed Web of Science ®Google Scholar
• De Maeseneer JM, van Driel ML, Green LA, et al. The need for research in primary care. Lancet 2003;362:1314–19
   PubMed Web of Science ®Google Scholar
• Carpenter JS, Byrne MM, Studts JL. Factors related to menopausal symptom management decisions. Maturitas 2011;70:10–15
   PubMed Web of Science ®Google Scholar
• Schaffer AL, Buckley NA, Dobbins TA, et al. The crux of the matter: did the ABC’s Catalyst program change statin use in Australia? Med J Aust 2015;202:591–5
   PubMed Web of Science ®Google Scholar
• Cifcili SY, Akman M, Demirkol A, et al. “I should live and finish it”: a qualitative inquiry into Turkish women's menopause experience. BMC Fam Pract 2009;10:2
   PubMed Web of Science ®Google Scholar
• Sayakhot P, Vincent A, Teede H. Breast cancer and menopause: perceptions of diagnosis, menopausal therapies and health behaviors. Climacteric 2012;15:59–67
   PubMed Web of Science ®Google Scholar
• Hyde A, Nee J, Drennan J, et al. Hormone therapy and the medical encounter: a qualitative analysis of women's experiences. Menopause 2010;17:344–50
   PubMed Web of Science ®Google Scholar
• Buhling KJ, Studnitz F. S G v, Jantke A, et al. Attitude of German gynecologists towards prescribing HRT before and after the WHI study. Climacteric 2012;15:326–31
   PubMed Web of Science ®Google Scholar
• Sangi-Haghpeykar H, Poindexter AN. Physicians’ views and practices concerning menopausal hormone therapy. Maturitas 2007;56:30–7
   PubMed Web of Science ®Google Scholar
• Dillaway HE. Medicalization survived the Women's Health Initiative … But, has discourse opened up? Women's Reprod Health 2015;2:24–8
   Google Scholar
• LaCroix AZ, Chlebowski RT, Manson JE, et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA 2011;305:1305–14
   PubMed Web of Science ®Google Scholar
• Sarrel PM, Njike VY, Vinante V, et al. The mortality toll of estrogen avoidance: An analysis of excess deaths among hysterectomized women aged 50 to 59 Years. Am J Public Health 2013;103:1583–8
   PubMed Web of Science ®Google Scholar
• Rocca WA, Grossardt BR, Shuster LT. Oophorectomy, menopause, estrogen treatment, and cognitive aging: Clinical evidence for a window of opportunity. Brain Res 2011;1379:188–98
   PubMed Web of Science ®Google Scholar
• Faubion SS, Kuhle CL, Shuster LT, et al. Long-term health consequences of premature or early menopause and considerations for management. Climacteric 2015;18:483–91
   PubMed Web of Science ®Google Scholar
• Kling JM, Manson JE. The Women's Health Initiative: evolving insights over 15 years. Menopause 2017;24:355–7
   PubMed Web of Science ®Google Scholar
• Cryer JD, Chan K-S, Time series analysis: With applications in R. New York, NY: Springer; 2008:249–76
   Google Scholar